We supplemented our data with data on drug company disclosures of payments to patient organisations we previously collected for "Exposing drug industry funding of UK patient organisations" (https://doi.org/10.1136/bmj.l1806). The only change we made to the data was extended the yearly range (from 2012-2016 to 2012-2018). We extracted relevant payments (namely payments made to patient organisations which had also supported APPGs) from the data.